Research programme: amyloid-beta inhibitors - Eisai/TorreyPines Therapeutics

Drug Profile

Research programme: amyloid-beta inhibitors - Eisai/TorreyPines Therapeutics

Alternative Names: Amyloid-beta42 modulators; Aβ42 modulators; NGX-96992; Series 591 compounds

Latest Information Update: 22 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TorreyPines Therapeutics Inc
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 22 Oct 2008 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
  • 04 Oct 2006 TorreyPines Therapeutics has merged with Axonyx to from TorreyPines Therapeutics, Inc.
  • 08 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Alzheimer's disease and cognition disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top